At the time of relapse , agents directed at activated pathways in MCL cells such as bortezomib ( NFkB inhibitor ) , lenalidamide ( anti-angiogenesis ) and Ibruitinib ( Bruton's Tyrosine Kinase [ BTK ] inhibitor ) have demonstrated excellent clinical activity in MCL patients .